And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, once again, rather modest. We plan to catch up on our reading, indulge ourselves with a few naps, hang with one or more short people, and take in another installment in our Let’s-see-them-before-they-die concert series. And what about you? This is a good time to sample some of those moving pictures that recently won awards. You could curl up with a good e-book or make time for someone special. Or start placing bets on the next big election. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.
Pfizer (PFE) received a request for documents as part of a U.S. investigation into quality-control problems at a subsidiary that makes the EpiPen device for Mylan (MYL), according to a regulatory filing. In 2017, the Meridian Medical Technologies unit was cited by regulators for a failure to investigate “serious” problems associated with an unspecified number of patient deaths. Within days of an FDA inspection, Mylan began recalling EpiPen devices from the U.S., Europe, Asia, and North and South America due to a product defect that, at the time, Mylan claimed “occurs rarely.”